EUVIMEDEUVIMED entdecken
Crossref

Novel immunotherapy in follicular lymphoma: a narrative review

Arushi Khurana, Stephen M. Ansell

Annals of Lymphoma · 2021

DOI: 10.21037/aol-20-48 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Lymphoma, 2021. Verfasst von Arushi Khurana und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL), a prototypical indolent lymphoma, is characterized by a prolonged survival with multiple relapses and the intermittent need for therapy. Therapeutic advances in the last two decades have contributed significantly to this extended survival. Manipulating various components of the immune system that form an integral part of the tumor microenvironment have been clinically beneficial. Mechanisms by which these immunotherapies work involve either directly targeting the lymphoma cells and using the immune system for effector function, thereby eliminating lymphoma cells, or by targeting the immune system cells to promote anti-tumor surveillance and generate an effective anti-tumor immune response. Newer generation monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies, and cellular therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have shown significant efficacy in FL. Also, these non-chemotherapy options boast a relatively favorable, albeit unique, toxicity profile. Patients with poor prognostic factors such as those with progression within 24 months from frontline therapy have an unmet need for newer and efficacious therapies. Bispecifics and cellular therapies such as CAR-T therapy look promising in this regard. However, careful consideration is required to identify the most suitable patients and the timing of each approach, thereby devising combinations that work synergistically and provide durable remissions while minimizing toxicity. This review focuses on novel immunotherapies currently approved or under clinical testing in FL patients.

Zitieren

APA

Khurana, A., & Ansell, S. M. (2021). Novel immunotherapy in follicular lymphoma: a narrative review. Annals of Lymphoma. https://doi.org/10.21037/aol-20-48

Vancouver

Khurana A, Ansell SM. Novel immunotherapy in follicular lymphoma: a narrative review. Annals of Lymphoma. 2021. doi:10.21037/aol-20-48

BibTeX
@article{Khurana2021,
  author = {Khurana, Arushi and Ansell, Stephen M.},
  title = {Novel immunotherapy in follicular lymphoma: a narrative review},
  journal = {Annals of Lymphoma},
  year = {2021},
  doi = {10.21037/aol-20-48}
}
Kostenlos starten →